Overview

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
0
Participant gender:
All
Summary
The most prevalent monogenetic diabetic subtype is named maturity onset diabetes of the young type (MODY3) or hepatocyte nuclear factor 1α (HNF1A)-diabetes. The aim of this study is to evaluate the effects of supra-physiological levels of GIP and GLP-1, respectively, on insulin and glucagon secretion at fasting plasma glucose (FPG) and "post-prandial" PG levels (1.5 × FPG) in patients with HNF1A-diabetes and matched healthy controls treated with or without a low dose of glimepiride (sulphonylurea). In addition, we will evaluate the maximal insulin and glucagon secretory capacity in both groups.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Treatments:
Gastric Inhibitory Polypeptide
Glimepiride
Glucagon
Glucagon-Like Peptide 1
Criteria
Participants

Ten patients with HNF1A-diabetes and ten matched healthy controls will be recruited.
Different inclusion and exclusion criteria applies for the two groups:

Inclusion criteria for HNF1A-patients

- Patients with HNF1A-diabetes verified by genetic testing

- Patients treated with diet or sulphonylurea monotherapy

- Normal haemoglobin (males 8.3-10.5 mmol/l, females 7.3-9.5 mmol/l)

- Informed consent

Exclusion criteria for HNF1A-patients

- Nephropathy (estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2 and/or
albuminuria)

- Liver disease (serum alanine aminotransferase (ALT) and/or serum aspartate
aminotransferase (AST) above 2 × normal values)

- Pregnancy or breastfeeding

Inclusion criteria for healthy controls

- FPG ≤6 mmol/l and glycated haemoglobin (HbA1c) ≤43 mmol/mol

- Normal haemoglobin as defined above

- Age ≥18 years

- Informed consent

Exclusion criteria for healthy controls

- No family history of type 1 or type 2 diabetes

- Nephropathy (defined above)

- Liver disease (defined above)

- Pregnancy or breastfeeding